Double Duty for CCL21 in Dendritic Cell Trafficking  by Murphy, Philip M.
Immunity
PreviewsKyei, G.B., Dinkins, C., Davis, A.S., Roberts, E.,
Singh, S.B., Dong, C., Wu, L., Kominami, E.,
Ueno, T., Yamamoto, A., et al. (2009). J. Cell Biol.
186, 255–268.
Lee, H.K., Mattei, L.M., Steinberg, B.E., Alberts, P.,
Lee, Y.H., Chervonsky, A., Mizushima,N., Grinstein,
S., and Iwasaki, A. (2010). Immunity 32, 227–239.590 Immunity 32, May 28, 2010 ª2010 ElseviLevine, B., and Deretic, V. (2007). Nat. Rev. Immu-
nol. 7, 767–777.
Nakatogawa, H., Ichimura, Y., and Ohsumi, Y.
(2007). Cell 130, 165–178.
Sanjuan, M.A., Dillon, C.P., Tait, S.W., Moshiach,
S., Dorsey, F., Connell, S., Komatsu, M., Tanaka,er Inc.K., Cleveland, J.L., Withoff, S., et al. (2007). Nature
450, 1253–1257.
Schmid, D., and Munz, C. (2007). Immunity 27,
11–21.
Schmid, D., Pypaert, M., and Mu¨nz, C. (2007).
Immunity 26, 79–92.Double Duty for CCL21
in Dendritic Cell TraffickingPhilip M. Murphy1,*
1Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,
MD 20892, USA
*Correspondence: pmm@nih.gov
DOI 10.1016/j.immuni.2010.05.004
Mechanisms controlling leukocyte adhesion, propulsion and directional migration have not been fully inte-
grated. In this issue of Immunity, Schumann et al. (2010) propose that DCs swarm to T cell zones using
immobilized CCL21 for adhesive random migration and soluble CCL21 for steering.The discovery by Metchnikoff more than
a century ago that phagocytes migrate
by crawling raised fundamental questions
about the adhesive properties of the
crawling surface and how they might facil-
itate movement. Adhesive migration is
also referred to as haptic movement.
The word ‘‘haptic,’’ from the Greek ‘‘hap-
testhai’’ meaning ‘‘to touch,’’ signifies the
adhesion of a cell to a surface. Two prin-
cipal types of haptic movement can
be distinguished: haptokinesis, where
‘‘kinesis’’ is the Greek word for ‘‘motion
or movement,’’ and haptotaxis, where
‘‘taxis’’ is Greek for ‘‘order.’’ Thus, hapto-
kinesis is movement of a cell along a
surface, but it is generally meant to
convey random movement, as opposed
to haptotaxis, which is meant to convey
ordered or directional movement of a
cell along a surface, where directional
cues are provided by gradients of bound
ligands recognized by receptors on the
migrating cell. In vitro assays have also
been used for identifying migration that
is dependent on soluble chemoattractant
ligands, which may be either chemoki-
netic in nature, if the concentration of che-
moattractant is uniform and movement is
nonvectorial, or chemotactic, if the con-
centration of chemoattractant is nonuni-form and the cell moves in a directional
manner defined by the gradient.
In the early 1990s, efforts to understand
leukocyte transendothelial migration re-
sulted in the multistep model of leukocyte
trafficking, a synthesis of research in the
areas of adhesion and directional migra-
tion (Butcher, 1991; Springer, 1994).
Other models were developed in special-
ized sites such as the lymph node, where
lymphocytes and dendritic cells (DCs)
appear to migrate along tracks defined
by fibroblastic reticular cells (FRCs) and
conduits decorated by chemokines and
adhesion molecules (Germain, 2006;
Baje´noff et al., 2007). Chemoattractants
were initially thought to be presented as
soluble factors, but later evidence for
tethering to surfaces was reported, and
tethering mechanisms were identified,
including genetically encoded transmem-
brane domains and binding to glycosami-
noglycans (GAGs) (Handel et al., 2005).
Still, the precise mechanism of migra-
tion has been difficult to define, and
certain details are not consistent or do
not fit the models at all. In particular,
diverse biophysical states of chemoat-
tractants could be defined, including obli-
gate soluble chemoattractants, obligate
membrane-bound chemoattractants, andchemoattractants that could be either
soluble or membrane bound, converted
through cleavage by specific enzymes.
Importantly, soluble chemoattractants
have been found to induce adhesion-
independent leukocyte migration (La¨m-
mermann et al., 2008).
These complexities are particularly
well-illustrated by the key lymph node
chemokine receptor CCR7 and its ligands
CCL19 and CCL21 (Fo¨rster et al., 1999).
CCR7 is expressed on naive T cells,
central memory T cells, and mature DCs.
CCL21 and, to a much lesser extent,
CCL19 are produced by FRCs. Why two
chemokines exist that bind to the same
homeostatic receptor with similar affinity
has been a mystery. A potential key to
understanding the specific roles of
CCL19 and CCL21 is their striking differ-
ence in structure: CCL21 has an extended
C terminus that mediates GAG binding,
whereas CCL19 lacks this domain and
as such is an obligate soluble chemokine.
With these observations in hand, the field
was poised for a new synthesis for under-
standing leukocyte migration, this time
between kinetic and tactic mechanisms,
as described for the CCR7 system in this
issue of Immunity by Schumann et al.
(2010). This elegant study, based on
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Figure 1. CCL21 Regulation of Mature
Dendritic Cell Trafficking to T Cell Zones
In this model, proposed by Schumann et al., DCs
undergo adhesive random migration (thin arrows)
on fields of immobilized CCL21 (large red symbols)
and ICAM-1 (not shown) that becomes direction-
ally biased in response to concentration gradients
of truncated soluble CCL21 (small red symbols),
generated from the immobilized chemokine by
the DC itself. Soluble CCL21 forms gradients and
biases the direction of migration (thick arrow).
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Previewsex vivo and in vitro model systems of
adhesion and migration, represents an
important conceptual advance in the
field.
The authors show stunning videos of
mature DCs swarming across lymph
node slices at specific physiologic entry
points, concentrating specifically into
T cells zone, where they stop. They show
that bisecting the lymph node section and
rotating one half of the section 180 rela-
tive to the other did not affect swarming,
thus proving that directional cues in this
system could not be haptic. So they
searched for soluble factors. Because
DC migration to the lymph node is known
to require CCR7, the authors tested this
receptor in their system and found that
migration was dependent on CCR7
expression on the DC. Immature DCs andother CCR7 negative leukocytes were
inactive in the assay. Moreover, DC
migration on purified CCL21 in vitro ap-
peared to be haptokinetic but was able
to generate a soluble chemotactic factor
that was also specific for CCR7. In vitro
under agarose assays with molecularly
tagged CCL21 tracked a proteolytic
activity specific to the DC that was able
to cleave the C terminus of CCL21 to
release a soluble fragment that appeared
to diffuse, form gradients, and provide a
second nested chemotactic signal. Inter-
estingly, the cleaved fragment corre-
sponded to the GAG-binding domain of
CCL21, the region that is lacking in
CCL19, which mediates adhesion-inde-
pendent chemotaxis. The authors found
that CCL21 decorates the reticular net-
work specifically in T cell zones in lymph
node providing haptokinetic tracks for
CCR7-positive DCs. Adhesion requires
DC expression of b2 integrins, which are
activated by immobilized but not soluble
CCL21. Finally, the authors developed
a 3D gel carbon fiber system to interro-
gate the importance of soluble chemokine
in biasing the direction of migration. In this
system, DC adhesion to the fiber required
both ICAM-1 and CCL21 on the fiber and
CCR7 and b2 integrins on the DC. Migra-
tion was nondirectional in the absence of
soluble chemokine, but could be strongly
directionally biased by the introduction of
gradients of either soluble CCL19 or
CCL21.
The principal significance of this paper
is that it separates experimentally for the
first time the adhesive and chemotactic
function of a chemokine in the same
system. The data support a model in
which DC migration to T cell zones occurs
on a reticular network decorated with im-
mobilized CCL21 (Figure 1). As the cell
interacts with the network, bound CCL21
triggers CCR7 to activate b2 integrins on
the DC, thereby promoting cell adhesion
to the network via ICAM-1-integrin bind-
ing and random migration. Then, a DC-
specific protease cleaves CCL21 at the
GAG-binding domain releasing a soluble
short form of CCL21 that forms gradients
able to directionally bias the cell and
shape the migration path toward the
T cell zone.
This two-step model has the virtue of
being consistent with existing evidence
in vivo for the distribution of total CCL21
and for adjustable leukocyte swarmingImmunitywithin confined areas such as is found in
lymph nodes. The authors have provided
some in vivo support for it by directly
demonstrating that a shortened form of
CCL21 can be detected by immunoblot
in extracts from mouse lymph node. Yet
questions remain. Is this form soluble,
and is it generated in large enough
amounts relative to the putative soluble
form released from FRCs before binding
to GAGs? Moreover, does it form gradi-
ents, and is it located in the T cell zone
to function as the authors propose? These
are limitations to the interpretation and
challenges for future experiments. In fact,
difficulty with directly measuring chemo-
kine gradients in vivo has been an undying
source of angst and embarrassment for
a field whose central dogma relies on
the existence of such gradients.
Another challenge to the model is to
explain why the proposed gradient of
soluble CCL21 should develop in a man-
ner favoring movement toward the T cell
zone rather than away, or instead to
produce homogeneous distributions of
soluble CCL21. Also, it will be important
to identify the DC protease able to cleave
CCL21, to define the specific cleavage
site, and to design in vivo experiments
that might test the physiologic importance
of this modification. In addition, it will be
interesting to test whether the model is
unique to the CCR7 system in lymph
node, or whether it may apply generally
to the entire chemokine system operating
on tracks or at endothelial surfaces.
Most chemokines are similar in length
and bind GAGs via multiple loop regions,
not through terminal prosthetic domains
such as CCL21 (Handel et al., 2005). Con-
verting such chemokines from GAG-
binding to soluble forms by proteolysis is
probably not feasible. However, most
chemokine receptors have multiple che-
mokine ligands, some of which could act
preferentially on surfaces and others pref-
erentially as soluble ligands (Murphy et al.,
2000). This kind of information is simply
not available for most of the chemokine
system, so in this regard, the work of
Schumann et al. (2010) should serve as
a catalyst to fill this gap in knowledge.
Efforts to extend the authors’ findings to
T lymphocytes, which also enter T cell
zones in a CCR7-dependent manner, will
be challenged by the requirement for an
exit strategy, which does not apply to
DCs. Most T cells transiting lymph node32, May 28, 2010 ª2010 Elsevier Inc. 591
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Previewsare naive or central memory cells that
continue to express CCR7 on the way
out, presumably against the gradient the
authors propose or by a different route
altogether.
Perhaps most perplexing is why a che-
mokine should induce different functional
responses depending on the state in
which it is presented. Why do soluble
CCL19 and CCL21 not activate b2 integ-
rins on mature DCs, whereas immobilized
CCL21 does? There is a substantial litera-
ture on the effects of GAG binding on
chemokine quaternary structure, and the
existence of homo- and heterodimers of592 Immunity 32, May 28, 2010 ª2010 Elsevichemokine receptors; perhaps this will
be the next important synthesis in under-
standing of how leukocytes migrate.REFERENCES
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